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Chapter 1 
Introduction 
 
1.1 The Current State of Antibacterials 
 
 Community-associated and hospital-acquired infections of Staphylococccus 
aureus have increased in the past 20 years. S. aureus can cause skin and soft tissue 
infections such as folliculitis and impetigo or invasive infections like endocarditis and 
pneumonia. Which results in S. aureus being the most common cause of death and 
disease from an infection in the United States.1 This rise can be explained by the rise in 
antibiotic-resistant strains, mainly methicillin-resistant S. aureus (MRSA) and more 
recently, vancomycin-resistant strains.2 
 
 To further complicate matter of antibiotic resistance, there has been a steep 
decline in antibiotic drug development for about two decades. Largely due to unexpected 
complications with newer innovative approaches to drug design. Large-scale genomics 
have sparked target-based efforts, where proteins important to bacterial growth are 
utilized in high-throughput screening efforts. These proteins are then used in high-
throughput screens that produced small molecule “hits”, but the small molecules resulted 
in lack of permeability or solubility when applied to whole cell screens.3 Another cause for 
the decline in drug development is that major pharmaceutical companies and biotech 
companies have abandoned their antibiotic research, partly to pursue the larger profits of 
2 
chronic diseases and partly due to large amount of antibiotics already on the market such 
as the non-classical antifolate Trimethoprim (TMP).4 
 
1.2 Trimethoprim and the Folate Pathway   
 
 
 
 
 
TMP-resistance was very rare before 1983, more recently 28% of MRSA have 
been reported resistant to TMP. What was a useful treatment for MRSA, has been largely 
negated.5 Trimethoprim (TMP), a diaminopyrimidine antimicrobial as seen in Figure 1, is  
 
 
 
 
 
 
 
 
 
Figure 2. Folate Biosynthesis Pathway. Produced from Lehninger 
Principles of Biochemistry, 2008, 5th Edition 
Figure 1. TMP an inhbitior of DHFR 
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a broad-specturm antibiotic which includes S. aureus. It exhibits an excellent safety 
profile, easily administered orally, relatively inexpensive, and works through competitive 
inhibition of dihydrofolate reductase (DHFR), a focal point in the folate biosynthesis 
pathway. TMP also works together with sulphonamides, to form the drug combination co-
trimoxazole, which also targets folate biosynthesis.6 Figure 2 displays the essential steps 
in the folate pathway. DHFR catalyzes the reduction of dihydrofolate to tetrahydrofolate 
with the cofactor NADPH. Serine hydroxymethyltransferase then converts 
tetrahydrofolate to 5,10-methylene tetrahydrofolate, which is an important cofactor in 
biosynthesis of purine nucleotides, histidine and methionine amino acid, and the C1 unit 
transfer for the biosynthesis of deoxythimidine monophosphate (dTMP) production.7,8 
 
1.3 Bacterial Resistance in Antifolates 
 
Most TMP-resistant strains display one of two chromosomal mutations: 
H30N/F98Y or H149R/F98Y. The F98Y is assumed to be the biggest cause for the loss 
of affinity of TMP in the double mutant. The double mutant results in a 36-fold loss of 
activity of TMP against S. aureus DHFR, and it competes for hydrogen bonding with Leu5, 
which normally hydrogen bonds with N-4 amine nitrogen of TMP.9 
 
This increase in resistance to antifolates warrants the development of new 
compounds that will overcome the loss of affinity brought on by the mutations in MRSA. 
Research in the Wright and Anderson groups focuses on Structure Activity Relationship 
4 
(SAR) design, synthesis, and assay of new non-classical antifolates against TMP 
resistant bacteria. 
 
1.4 Propargyl-linked Antifolates 
 
1.4.1 First Generation Propargyl-linked Antifolates 
 
 TMP is an antifolate that is a selective inhibitor of E. coli and S. aureus DHFR over 
human DHFR. Whereas, methotrexate (MTX) is a nonselective inhibitor, but is more 
potent than TMP and is used mostly in cancer chemotherapy.11 This difference in 
selectivity and potency is the focus of the Wright group, to optimize TMP to be as potent 
as MTX, but maintain its selectivity towards E.coli and S. aureus. Through structural 
analysis of DHFR with TMP it was observed that the interaction between 2,4-
Figure 3. TMP and NADPH crystallized with S. 
aureus DHFR. Produced from Proteins, 2009, 76, 706-717. 
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diaminopyrimidine and an acidic residue is conserved among many different species of 
DHFR10. Shown in Figure 3, TMP forms four hydrogen bonding interactions with residues 
in the active site. The N1 and N2 on the diaminopyrimidine ring interacts with oxygen 
atoms of Asp27, and N4 amine hydrogen bonds with the carbonyl oxygen atoms of Leu5 
and Phe92. There are also several van der Waals interactions with Leu5, Val6, Ala7, 
Val31, Phe92, and the nicotinamide ring of NADPH. The trimethoxybenzyl group is in a 
hydrophobic pocket interacting with Leu20, Leu28, Ile50, Leu54 residues. The oxygens 
of the methoxy groups form hydrogen bonds with water molecules.12 
 
 A comparison of TMP with MTX displays that the trimethoxybenzyl group does not 
reach as far into the hydrophobic pocket as the pABA region of MTX. It is this observation 
that a plan was devised to extend the linker region to increase TMP activity. The linker 
length was increased to 3 carbon atoms and through trial and error of saturated, 
acetylene, and propargyl linkers it was determined that the 3 carbon propargyl linker 
afforded the best activity. The propargyl linker maintains the same number of degrees of 
freedom, and pushes the trimethoxybenze group further into the hydrophobic pocket.10  
 
1.4.2 Second Generation Propargyl-linked Antifolates 
 
Although the propargylic linker was relatively potent compared to TMP, its 
selectivity over human DHFR (hDHFR) was only 36-fold. To overcome this a C-ring was 
added on to the B-ring. It was observed that the opening to the active site in hDHFR is 
restricted by a four-residue loop of Pro61, Glu62, Lys63, and Asn64 also known as the 
6 
PEKN loop which is absent in ChDHFR. Through docking experiments as seen in Figure 
4, it was observed that a functionality added meta or para to the B-ring would interact with 
a region of space filled by the PEKN loop in hDHFR. This functionality would destabilize 
binding to hDHFR and maintain activity in ChDHFR.6 Compounds that were synthesized 
with the added functionality to the B-ring did increase selectivity, but were found to have 
issues with permeability/solubility. 
 
 
1.4.3 Third Generation Propargyl-linked Antifolates 
 
 The development of the propargyl-linked antifolates (PLA) occurred two fold, in the 
second generation increase potency and selectivity of enzyme inhibition and in the third 
generation improved the balance between solubility and permeability for these 
hydrophobic compounds. A pyridine ring was introduced to into these PLAs, and solubility 
was increased to an acceptable range of 40 ug/mL. Along with increased solubility it was 
Figure 4. Comparison of ChDHFR (right) and hDHFR (left) highlighting PEKN 
loop region. Produced from J. Med. Chem, 2008, 51, 6839-6852 
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noticed through crystal structure studies of these compounds forced a different 
conformation of the nicotinamide ring of NADPH in order to maintain π-π stacking. 
Enantiomers were synthesized to understand the efficacy of a single enantiomer and 
because current regulations state drugs must be enantiomerically pure. The enantiomers 
that were developed demonstrated that a change in configuration of the stereocenter 
drove the selection of the alternate NADPH conformation and had no antagonistic 
effects.13 Along with being potent inhibitors, the third generation PLAs have minimal 
cytotoxicity when tested against MCF-10 and HepG2 mammalian cell lines.14  
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Figure 5. Evolution of propargyl-linked antifolates from Trimethoprim 
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1.5 Gram-negative Pathogens 
 
1.5.1 Outer Membrane of Gram-negative Pathogens 
 
  
With the encouraging results from the optimization of TMP to the ABC ring, it is 
time to turn efforts towards activity against Gram-negative pathogens. They differ from 
Gram-positive pathogens in that they have a specialized outer membrane (OM) made up 
of a layer of lipopolysaccharides (LPS) and an inner membrane composed of 
phospholipids as seen in Figure 6. The main route of passage for compounds through the 
OM are through porins that allow non-specific diffusion of hydrophilic compounds with a 
Figure 6. Gram-negative pathogen membrane. Produced 
from Nature Reviews Microbiology, 2015, 13, 605-619 
9 
molecular weight less than 600 Da. The OmpF/OmpC- type porins have a preference for 
cations and don’t require phosphate starvation like PhoE-type porins.15 
 
 
1.5.2 Efflux pumps of Gram-negative Pathogens 
 
Along with having an outer membrane, Gram-negative bacteria also possess a 
complex system of cytoplasmic membrane, periplasmic, and outer membrane efflux 
pumps. They can be categorized into 5 different families: ATP-binding cassette (ABC) 
transporters, small multidrug resistance (SMR), resistance-nodulation-division (RND), 
and major facilitator superfamily (MFS). E. coli possess redundant efflux systems that 
have overlapping properties of the different classes, so a mutational loss of one efflux 
pump family does not make the pathogen susceptible to cytotoxic agents.16 
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1.6 Passage into Gram-negative Cytoplasm 
In order for a compound to enter the cytoplasm of a Gram-negative pathogen it 
needs to be hydrophilic and preferably cationic to pass into the periplasm, but also 
hydrophobic and uncharged to pass through the inner membrane into the cytoplasm. This 
of course creates a dilemma that is believed to be solved by designing a compound that 
is small, weakly charged or zwitterionic of low LogP that are uncharged at physiological 
pH. Figure 7 displays how most antibiotics on the market that are effective against Gram-
negative bacteria have a cLogP between 0-2 and molecular weight <600 Da.15 Currently 
most of the compounds developed in the Wright lab have a cLogP between 3-5. 
 
1.7 Development of seco-B Ring Antifolates 
 
Figure 7. MW vs. cLogP plot for antibacterials. Produced from Drug Discov. 
2008, 3, 5 
11 
 In effort to increase activity of our compounds in Gram-negative pathogens a plan 
was devised to remove the B-ring reducing lipophilicity, increasing flexibility, and lowering 
the MW. Another possible outcome of increasing the flexibility is that compound might 
become less susceptible to activity loss due to acquired resistance and pass through the 
lipid bilayer more freely. As seen below in Scheme 1, UCP1016 has cLogP of 3.30 and 
when the B-ring is removed there is a significant decrease in cLogP. After testing 2, 3, 
and 4 saturated carbon chain  
 
lengths, it was found that the 3 saturated carbon chain gave the best activity in Gram-
negative, and an improved MIC value compared to the B-ring compound17 as seen in 
Table 1. 
Scheme 1. Development of seco-B ring compounds 
N
NH2N
NH2
N
N
NH2N
NH2
N
N
NH2N
NH2
N
UCP1108
Molecular Weight: 295.39
CLogP: 3.00
UCP1103
Molecular Weight: 281.36
CLogP: 2.47
UCP1016
Molecular Weight: 329.41
CLogP: 3.30
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Compounds EcIC50 BW25113 cLogP 
TMP 
 
N
NH2N
NH2
OMe
OMe
OMe  
0.020 0.38 0.981 
UCP1016 
N
NH2N
NH2
N  
ND >20 3.30 
UCP1028 
N
NH2N
NH2
OH  
ND >20 4.13 
UCP1103 
N
NH2N
NH2
N
 
0.055 15 2.47 
UCP1149 
N
NH2N
NH2
OH
 
ND 10 3.30 
Table 1. Comparison of enzyme activity, cell activity, 
and partition coefficients of seco-B ring compounds to 
three ring antifolates in E. coli 
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1.8 Conclusions 
 
With the rise in resistance to antibiotics it is imperative that new antibiotics be 
developed to fight growing number of deaths caused by antibiotic resistant pathogens. 
DHFR is a key target in the folate pathway to develop new antibiotics, since it is essential 
to metabolic synthesis of nucleotides and amino acids. Resistance to TMP has sparked 
the design of Propargyl-linked antifolates, and further development is needed to design a 
potent pharmacophore that is active in both Gram-positive and Gram-negative bacteria. 
 
  
14 
References 
1. Van Horn, K.; Burda, W.; Fleeman, R., Shaw, L.; Manetsch, R., Antibacterial 
Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines, J. Med. 
Chem., 2014, 57, 3075-3093. 
2. http://emedicine.medscape.com/article/971358-overview#showall 
3. Bourne, C., Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial 
Discovery, Antibiotics, 2014, 3, 1-28. 
4. Coates, A.R.; Hu, Y., Novel approaches to developing new antibiotics for bacterial 
infections, J. Pharmacol., 2007, 152, 1147-1154. 
5. Dale, G.; Broger, C.; Arcy, A.; Hartman, P.; DeHoogt, R.; Jolidon, S.; Kompis, I.; 
Labhardt, A.; Langen, H.; Locher, H. et al. A single amino acid substitution in 
Staphylococcus aureus dihydrofolate reductase determines trimethoprim 
resistance, J. Mol. Bio., 1997, 266, 1-214. 
6. Vickers, A.; Potter, N.; Fishwick, C.; Chopra, I.; O’Neil, A., Analysis of mutational 
resistance to trimethoprim in Staphylococcus aureus by genetic and structural 
modelling techniques, J. Antimicrobial Chemotherapy, 2009, 63, 1112-1117. 
7. Bolstad, D.; Bolstad, E.; Frey, K.; Wright, D.; Anderson, A., Structure-Based 
Approach to the Development of Potent and Selective Inhibitors of Dihydrofolate 
Reductase from Cryptosporidium, J. Med. Chem., 2008, 51, 6839-6852. 
8. Dayanandan, N., Structure-Based Drug Design and Synthesis of Anti-infective and 
Anticancer Agents, Doctoral Dissertations, Paper 623. 
9. Frey, K.; Lombardo, M.; Wright, D.; Anderson, A., Towards the understanding of 
resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-
15 
resistant Staphylococcus aureus dihydrofolate reductase, J. Struct. Biology, 2010, 
170, 93-97. 
10. Pelphrey, P.; Popov, V., Joska, T.; Beierlein, J.; Bolstad, E.; Fillingham, Y.; Wright, 
D.; Anderson, A., Highly Efficient Ligands for Dihydrofolate Reductase from 
Cryptosporidium hominis and Toxoplasma gondii Inspired by Structural Analysis, 
J. Med. Chem., 2007, 50, 940-950. 
11. Beierlein, J.; Frey, K., Bolstad, D.; Pelphrey, P.; Joska, T.; Smith, A.; Priestley, N.; 
Wright, D.; Anderson, A., Synthetic and Crystallographic Studies of a New Inhibitor 
Series Targeting Bacillus anthracis Dihydrofolate Reductase, J. Med. Chem., 
2008, 51, 7532-7540. 
12. Heaslet, H.; Harris, M.; Fahnoe, K.; Sarver, R.; Putz, H.; Chang, J.; Subramanyam, 
C.; Barreiro, G.; Miller, J., Structural comparison of chromosomal and exogenous 
dihydrofolate reductase from Staphylococcus aureus in complex with the potent 
inhibitor trimethoprim, 2009, 76, 706-717. 
13. Keshipeddy, S.; Reeve, S.; Anderson, A.; Wright, D., Nonracemic Antifolates 
Stereoselectively Recruit Alternate Cofactors and Overcome Resistance in S. 
aureus, J. Am. Chem. Soc., 2015, 137, 8983-8990. 
14. Zhou, W.; Viswanathan, K., Hill, D.; Anderson, A.; Wright, D., Acetylenic Linkers 
in Lead Compounds: A Study of the Stability of the Propargyl-Linked Antifolates, 
Drug Metabolism and Disposition, 2012, 40, 2002-2008. 
15. Silver, L, Are natural products still the best source for antibacterial discovery? The 
bacterial entry factor, Expert Opin. Drug Discov., 2008, 3, 487-500. 
16 
16. Pagés, J.; Masi, M.; Barbe, J., Inhibitors of efflux pumps in Gram-negative bacteria, 
TRENDS Mol. Med., 2005, 11, 382-389 
17. Scocchera, E., Propargyl-linked antifolates: Rational design and synthesis of new 
antibacterials, UCONN: Medicinal Chemistry Seminar Presentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
Chapter 2 
Design and Development of seco-B Ring Compounds 
 
2.1 Hetero straight chain seco-B Ring Antifolates 
 
N
X
Br
K2CO3, MeCN, 85 0C N
X
Iodoethylpyrimidine, Pd(PPh3)2Cl2,CuI
KOAc, DMF, 60 0C
N
X
N
N
NH2
H2N
X= NH2, OH, or SH
70-100% yield 20-40% yield
 
Scheme 2. Synthesis of heterochain seco-B ring compounds 
 
To further lower the LogP a plan was devised to introduce heteroatoms into the 
straight chain of UCP1103. This resulted in UCP1150 (amine), UCP1152 (ether), and 
UCP1157 (sulfide). As you can see in Scheme 2 they were synthesized via nucleophilic 
attack into 4-bromobutyne with bromine as the leaving group resulting in the alkyne in 
high yield.1 Followed by a Sonagashira coupling of the alkyne to the diaminopyrimidine 
yielded the final compound.2 Although these compounds have a lower LogP, they 
displayed poor activity in both S. aureus and E. coli as seen in Table 2.  
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Compound cLogP 
SaIC50 
(µM) 
Sa MIC 
(µg/mL) 
EcIC50 
(µM) 
Ec MIC 
(µg/mL) 
UCP1103
N
N
N
NH2
H2N  
2.47 0.019 0.625 0.55 15 
UCP1150
N
H
N
N
N
H2N
NH2
 
1.91 2.322 >10 18.92 >20 
UCP1152
N
O
N
N
NH2
H2N  
1.86 0.405 >10 ND >20 
Table 2. Hetero chain compounds compared against the all carbon chain 
 
 
2.2 Sulfur-linked seco-B ring Compounds 
  
After the poor activity of UCP1150 and UCP1152, a crystal structure of UCP1103 
was obtained and it was observed that the failure in most of the heterochain compounds 
could be explained by the chain region being surrounded by nonpolar residues Phe31, 
Ile50, Leu54, and Ile94 (Figure 8). It was at this point that the use of a sulfur was 
envisioned because sulfur doesn’t hydrogen donate or accept like oxygen or nitrogen, 
and sulfur has similar electronegativity to carbon. In S. aureus UCP1157 displayed equal 
activity as the all carbon chain UCP1103 despite having a higher IC50.  
19 
 
 
Using the exact same synthetic route shown in Scheme 2, but with 4-
mercaptophenol instead of the pyridine, UCP1174 was synthesized, the sulfide version 
of UCP1149, and it also displayed equal activity as the all carbon chain in S. aureus. With 
sulfide compounds having the same activity as the all carbon chain in S. aureus, it was 
envisioned that using SN2 substitution reactions with thiols would be possible to test a 
wide range of functional groups on the C ring relatively quickly compared to the all carbon 
seco-B ring compounds some of which are shown in Table 3. 
 
 
 
Figure 8. Crystal structure of UCP1103 in E. coli DHFR 
20 
 
 
 
 
 
 
 
 
 
 
Table 3. Various functional groups on the C ring of seco-B ring compounds. 
 
 
2.3 Branched seco-B Ring Sulfide Compounds 
 
 
 The risk with sulfur in our compounds is that it could have a shorter half-life 
compared to the all carbon chain due to the carbon-sulfur bond being weaker and the 
potential for the sulfur to be easily oxidized. To circumvent this anticipated problem and 
to increase contacts with the hydrophobic residues around the straight chain portion of 
SaDHFR, a methyl group off of the chain next to the sulfur was synthesized using a Thiol 
Michael addition3 followed by a Bestmann-Ohira homologation4 forming the alkyne. 
 
C ring 
Functional 
Group 
S. aureus 
MIC 
C ring Functional 
Group 
S. aureus 
MIC 
UCP1157 
S
N   
0.625 
UCP1201 
S
O
OEt  
1.25 
UCP1174
S
OH  
0.313 
UCP1202
S
O
OH  
 
2.50 
UCP1199
S
NH2  
1.25 
UCP1203 
S
OH
OH  
>10 
21 
HS
OH
R2
O
1.1eq. TEA, DCM
R1
S
R2R1
O
OH
Ohira Bestmann
K2CO3, MeOH
S
R2R1 OH
Iodoethylpyrimidine, Pd(PPh3)2Cl2,CuI
KOAc, DMF, 60 0C
S
N
N
NH2
H2N
OH
R2R1
 
Scheme 3. Synthesis of branched sulfide alkynes 
 
 
The addition of a methyl group off of the chain resulted in a decrease in S. aureus MIC 
as seen in Table 4, 0.0781 µg/ mL. This prompted further development into increasing 
hydrophobic contacts in the chain region of SaDHFR resulting in S. aureus MIC of 0.0195 
µg/ mL for UCP1192, the dimethyl version of the compound. 
 
 
 
Compound R1 R2 S. aureus MIC (µg/ mL) 
UCP1174 H H 0.3125 
UCP1176 H -CH3 0.0781 
UCP1192 -CH3 -CH3 0.0195 
UCP1193 H -CH2CH3 0.0781 
Table 4. Activity of branched sulfides in S.Aureus 
 
  
A crystal structure of UCP1192 was obtained observed that the quartenary carbon 
with two methyl groups acted as the B ring by making the same contacts, Leu20, Thr46, 
and NADPH, as the B ring in UCP1106 as can be seen in Figure 9. Additionally, UCP1192 
S
N
N
NH2
H2N
OH
R2R1
22 
has a Log P of 3.78 compared to UCP1106 4.38. The key difference between UCP1106 
and UCP1192 in terms of contacts with SaDHFR is that the zwitterion (UCP1106) makes 
a hydrogen bonding contact with Arg57 through a water molecule. Instead the C ring of 
Figure 9. Comparison of UCP1106 (top) and 
UCP1192 (bottom) 
23 
UCP1192 favors Lys52 resulting in no hydrogen bonding contacts. There is no clear 
explanation for why UCP1192 has an alternate conformation than UCP1106, but the 
increase in degrees of freedom might be a possible explanation.  
 
2.4 Sulfur-linked seco-B Rings in EcDHFR 
 
 Although the sulfur-linked seco-B rings have shown high activity in S. aureus, they 
have struggled in the E. coli cell lines. Even the most active compounds in S. aureus fail 
to get MIC values less than 20 µg/mL. As we mentioned earlier in order for compounds 
to pass through the OM of a Gram-negative pathogen it needs to be hydrophilic and 
cationic in nature. Sulfur having a large electron cloud possibly gives these compounds 
anionic character, making it difficult to pass through the OM. These sulfur-linked 
compounds are still a valuable resource when designing compounds because the two to 
three step synthesis of these compounds allow a person to test different functional groups 
relatively quickly. Comparing the results in Table 5 it can be inferred that UCP1192 could 
be a potent inhibitor of E. coli if transformed into the all carbon chain form. UCP1192 is 
relatively potent in NR698 cell line. This cell line has a compromised cell layer, and if a 
compound it potent in NR698 cell lines, but not in the fully functional BW25113 then it can 
be assumed that the poor activity is due to the compounds inability to pass through the 
outer membrane. For example, UCP1203 would be a poor inhibitor, but instead of using 
a 5 to 6 step synthesis to determine if a diol on the C ring would be an active inhibitor, it 
was synthesized in 2 steps using the sulfur linkage. 
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    Table 5. Sulfur-linked seco-B ring compounds in E. coli DHFR 
 
 
 
 
 
Compound BW25113 JW0451 NR698 
UCP1157 
N
S
N
N
NH2
H2N  
>20 2.5 0.3125 
UCP1174 
S
N
N
NH2
H2N
OH
 
>20 5 0.0781 
UCP1192 
S
N
N
NH2
H2N
OH
 
>20 2.5 0.02 
UCP1199 
S
N
N
NH2
H2N
NH2
 
 
>20 10 0.156 
UCP1203 
S
OH
N
N
NH2
H2N
OH
 
>20 20 2.5 
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2.5 Hydrogen Bonding Network Observation in EcDHFR 
 
 While observing the crystal structure of UCP1103 it was noticed that there was a 
water network just off the straight chain involving Glu17, Thr46, Tyr100, and the nitrogen 
atom of Ile94, (Figure 10). 
 
 
To increase binding affinity, UCP1194 was designed and synthesized to have a hydroxy 
functional group on the carbon next to the alkyne which would interact with the water 
network. As shown in Sceme 4, first a Wittig reaction5 and then hydrogenation of 4-
pyridinecarboxaldehyde to make the commercially available 4-pyridinepropanol. Dess-
Martin oxidation6 to commercially available 4-pyridinepropanal followed by TMS-alkyne 
addition7 into the carbonyl gave the hydroxyl group of the chain. TMS deprotection 
Figure 10. Water network in EcDHFR 
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followed by the Sonagashira reaction gave UCP1194.  Unfortunately, UCP1194 resulted 
in loss of activity in both E. coli and S. aureus. 
Scheme 4. Synthesis of UCP1194 
 
 
2.6 Sulfate in EcDHFR 
 
 Another observation made in the crystal structure of UCP1103 in EcDHFR is the 
presence of a sulfate ion that is hydrogen bonding with Lys32, Arg52, and Arg57 of the 
Figure 11. Sulfate stabilization of EcDHFR 
N
O Ph3P
O
Kt-BuO, THF
1.
2. H2, Pd/C
N
HO
Dess-Martin
0.1 eq H2O, DCM N
O
1. TMS-alkyne, BuLi, THF
2. K2CO3, MeOH N
OH
Iodoethylpyrimidine, Pd(PPh3)2Cl2,CuI
KOAc, DMF, 60 0C N
N
N
NH2
H2N
OH
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enzyme and is located near the C ring of UCP1103.  To improve enzyme affinity and 
activity UCP1202 was synthesized. Placing an acetic acid off the C ring should put the 
carboxylic acid functional group in the proper position to replace the sulfate. UCP1202 
has shown no increase in activity in any of the E. coli cell lines. Having >20 µg/mL in 
BW25113, 20 µg/mL in JW0451 (efflux pump deficient), and 2.5 µg/mL in NR698 
(compromised LPS layer). There are ongoing efforts to add a sulfate to UCP117498 or 
addition of sulfamide to UCP11999 to try and probe the sulfate network.  
 
2.7 Conclusion 
 
 The speed and low cost of using thiols for substitution reactions makes for a useful 
tool in testing different functional groups relatively quickly compared to the all carbon 
seco-B ring compounds. Furthermore, the use of thiols in Michael additions can generate 
a wide range of substrates with varying carbon chain lengths alpha to the sulfur. The 
crystal structure of UCP1192 gives insight into future compound directions. 
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Chapter 3 
Experimental Procedures 
General Experimental. All reactions, unless specified, were conducted under an 
atmosphere of Argon in glassware that had been flame dried. Methylene chloride (CH2Cl2) 
was used from Baker Cycle-Tainers, and anhydrous toluene, dioxane, and trimethylamine 
purchased from Sigma-Aldrich. Dimethylformamide (DMF) was purchased from Acros. 
Josiphos was purchased from STREM. Where appropriate, control of temperature was 
achieved with an ice-bath or a heated oil bath. 1H NMR spectra were recorded at 400 
MHz, and/or at 500 MHz and calibrated to the CDCl3 peak at 7.28 ppm. 13C NMR spectra 
were recorded at 100MHz, and/or at 125 MHz and calibrated to the CDCl3 peak at 77.23 
ppm. Chemical shifts are reported in units of parts per million (ppm). High-resolution mass 
spectra were obtained on the JMS-AX505HA instruments and/or on an AccuTOF 
instrument at the University of Connecticut. IR spectra were obtained on the Bruker FT-
IR instrument at the University of Connecticut. Flash chromatography was performed on 
Silica Gel, 40 microns, 32-63 flash silica and/or -NH2 capped spherical silica gel. Thin 
layer chromatography was performed on silica gel (Silica Gel 60 F254) glass plates and 
the compounds were visualized by UV and/or potassium permanganate stain. 
 
Synthesis of pyridine homopropargyl amine.  
 
 
To a solution of 4-amino pyridine (500 mg, 5.30 mmol) in Acetonitirile (25 mL), K2CO3 
(2.95 g, 10.7 mmol) and was stirred for 10 minutes. 4-Bromo-butyne (1.00 mL, 10.7 mmol) 
N
N
H
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was added. The reaction vessel was sealed, and the mixture was kept stirring and heated 
for 16 hours at 85 °C. The reaction mixture was then filtered through celite and washed 
with ether. The solution was then concentrated on a rotary evaporator. Yielded yellow 
solid (779 mg, 98% yield); mp 145 °C; 1H NMR (500 MHz, Methanol-d4) δ 8.03 (d, J = 
7.3 Hz, 2H), 6.86 (d, J = 7.2 Hz, 2H), 4.27 (t, J = 6.2 Hz, 2H), 2.77 (td, J = 6.2, 2.6 Hz, 
2H), 2.27 (t, J = 2.5 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ 159.18, 143.56, 109.60, 
80.26, 74.94, 55.51, 20.54; IR (neat cm-1) 3311, 3252, 3235, 3198, 3153, 1647, 1545, 
1533, 1508; HRMS (DART, M++H) m/z 147.0899 (calculated for C9H11N2, 147.0922) 
Synthesis of inhibitor UCP1150.  
 
 
 
To alkyne (111 mg, 0.758 mmol), iodo-ethyl pyrimidine (100 mg, 0.378 mmol), CuI (3.60 
mg, 0.0190 mmol), PdCl2(PPh3)2 (40.0 mg, 0.0560 mmol), and potassium acetate (372 
mg, 3.78 mmol) was added followed by DMF (16 mL) and stirred at 65 ° C for an hour. 
The reaction mixture was quenched with solid sodium bicarbonate and filtered through 
cotton, and concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient 
flash chromatagrophy with amine silica gel (EtOAc followed by 1 % to 10% MeOH in 
CH2Cl2) to yield coupled pyrimidine as a brown solid (33.0 mg, 31% yield); mp 122 °C; 1H 
NMR (500 MHz, Methanol-d4) δ 8.16 (d, J = 7.5 Hz, 2H), 6.85 (d, J = 7.5 Hz, 2H), 4.37 
(t, J = 6.3 Hz, 2H), 3.10 (t, J = 6.3 Hz, 2H), 2.46 (q, J = 7.7 Hz, 2H), 1.09 (t, J = 7.6 Hz, 
3H); 13C NMR (126 MHz, Methanol-d4) δ 172.58, 164.90, 161.16, 159.57, 142.72, 109.26, 
92.46, 88.44, 76.65, 56.07, 28.64, 21.37, 11.77; IR (neat cm-1) 3311, 3252, 3235, 3198, 
N
H
N
N
N
H2N
NH2
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3153, 1653, 1620,1565, 1540; HRMS (ESI, M++H) m/z 283.1660 (calculated for C15H19N6 
283.1671) 
Synthesis of pyridine homopropargyl ether 
 
 
To a solution of 4-hydroxy pyridine (500 mg, 5.26 mmol) in Acetonitirile (25 mL), K2CO3 
(2.91 g, 21.0 mmol) and was stirred for 10 minutes. 4-Bromo-butyne (1.50 mL, 15.8 mmol) 
was added. The reaction vessel was sealed, and the mixture was kept stirring and heated 
for 16 hours at 100 °C. The reaction mixture was then diluted with water and extracted 
with EtOAc (100 mL) and then CH2Cl2 (100 mL). The CH2Cl2 portion was then dried with 
Na2SO4 and concentrated. Yielded a yellow semi-solid (200 mg, 26% yield); 1H NMR (500 
MHz, Methanol-d4) δ 7.70 (d, J = 7.0 Hz, 2H), 6.56 (d, J = 7.1 Hz, 2H), 4.08 (t, J = 6.3 
Hz, 2H), 2.68 (td, J = 6.3, 2.6 Hz, 2H), 2.11 (t, J = 2.6 Hz, 1H); 13C NMR (126 MHz, 
Methanol-d4) δ 141.80, 117.89, 78.64, 72.95, 55.81, 21.14; IR (neat cm-1) 3285, 1635, 
1529; HRMS (DART, M++H) m/z 148.0744 (calculated for C9H10NO 148.0762);  
Synthesis of UCP1152 
N
O
N
N
NH2
H2N  
To alkyne (200 mg, 1.36 mmol), iodo-ethyl pyrimidine (180 mg, 0.680 mmol), CuI (6.48 
mg, 0.0340 mmol), PdCl2(PPh3)2 (71.5 mg, 0.100 mmol), and potassium acetate (670 mg, 
6.79 mmol) was added followed by DMF (10 mL) and stirred at 65 ° C for an hour. The 
reaction mixture was quenched with solid sodium bicarbonate and filtered through cotton, 
N
O
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and concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (EtOAc followed by 5 % to 20% MeOH in CH2Cl2) to yield coupled 
pyrimidine as a white solid (69.3 mg, 36% yield); mp 228 0C; 1H NMR (500 MHz, 
Methanol-d4) δ 7.79 (d, J = 7.2 Hz, 2H), 6.48 (d, J = 7.3 Hz, 2H), 4.19 (t, J = 6.4 Hz, 2H), 
3.04 (t, J = 6.4 Hz, 2H), 2.53 (q, J = 7.6 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H); 13C NMR (126 
MHz, Methanol-d4) δ 175.39, 168.95, 160.36, 113.72, 88.63, 51.48, 25.03, 18.00, 8.24; 
IR (neat cm-1) 3285, 3119, 1640, 1546; HRMS (DART, M++H) m/z 284.1506 (calculated 
for C15H18N5O 284.1511) 
Synthesis of homopropargyl pyridine sulfide 
 
 
To a solution of 4-mercapto pyridine (500 mg, 4.5 mmol) in Acetonitrile (15 mL), K2CO3 
(1.3 g, 9.0 mmol) was added and allowed to stir for 10 minutes. 4-Bromo-butyne (0.84 
mL, 9.0 mmol) was added. The reaction vessel was sealed and the mixture was stirred 
at 100 °C for an hour. The reaction mixture was then diluted with water (25 mL) and 
extracted with EtOAc (150 mL) and then dried with Na2SO4 and concentrated. The crude 
product was purified by flash chromatography (10% to 40 % EtOAc in Hexanes) to yield 
pure product as a brown solid (0.36 grams, 49% yield); mp 37 0C; 1H NMR (500 MHz, 
Chloroform-d) δ 8.26 (d, J = 4.9 Hz, 2H), 6.97 (d, J = 4.9 Hz, 2H), 3.01 (t, J = 7.4 Hz, 2H), 
2.43 (td, J = 7.3, 2.4 Hz, 2H), 2.03 (d, J = 2.6 Hz, 1H); 13C NMR (101 MHz, Chloroform-
d) δ 149.49, 147.92, 120.84, 70.39, 29.59, 18.89; IR (neat cm-1) 3290, 3130, 2926, 1720, 
1568; HRMS (DART, M++H) m/z 164.0545 (calculated for C9H10NS 164.0534) 
 
N
S
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Synthesis of UCP1157 
 
 
 
To alkyne (120 mg, 0.740 mmol), iodo-ethyl pyrimidine (100 mg, 0.370 mmol), JosiPhos 
Copper (1.50 mg, 0.000920 mmol), Pd(PPh3)4 (43.4 mg, 0.0370 mmol), and potassium 
acetate (180 mg, 1.84 mmol) was added followed by DMF (5 mL) and stirred at 85 ° C for 
an hour. The reaction mixture was quenched with solid NaHCO3 and filtered through 
cotton, and concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient 
flash chromatagrophy (EtOAc followed by 1 % to 5% MeOH in CH2Cl2) to yield coupled 
pyrimidine as a yellow solid (43.8 mg, 36% yield); mp 170 0C; 1H NMR (500 MHz, 
Chloroform-d) δ 8.33 (d, J = 6.2 Hz, 2H), 7.16 (d, J = 6.2 Hz, 2H), 3.23 (t, J = 6.9 Hz, 2H), 
2.88 (t, J = 6.9 Hz, 2H), 2.62 (q, J = 7.6 Hz, 2H), 1.18 (t, J = 7.6 Hz, 3H); 13C NMR (126 
MHz, Chloroform-d) δ 173.10, 164.31, 160.45, 148.83, 121.06, 95.63, 89.88, 75.35, 
53.42, 30.27, 29.35, 19.85, 12.47; IR (neat cm-1)  3313, 3113, 2971, 2925, 1635, 1560; 
HRMS (DART, M++H) m/z 300.1302 (calculated for C15H18N5S 300.1283) 
Synthesis of homopropargyl phenol sulfide 
 
To a solution of 4-mercapto phenol (500 mg, 3.96 mmol) in Acetonitrile (15 mL), K2CO3 
(603 mg, 4.36 mmol) was added and allowed to stir for 10 minutes. 4-Bromo-butyne 
(0.410 mL, 4.36 mmol) was added. The reaction vessel was sealed and the mixture was 
stirred at 100 °C for an hour. The reaction mixture was then diluted with water (25 mL) 
and extracted with EtOAc (150 mL) and then dried with Na2SO4 and concentrated. The 
N
S
N
N
NH2
H2N
S
OH
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crude product was purified by flash chromatography (10% to 40 % EtOAc in Hexanes) to 
yield pure product as a brown solid (691 mg, 98% yield); mp 48 0C; 1H NMR (500 MHz, 
Chloroform-d) δ 7.36 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.17 (s, 1H), 2.98 (t, J 
= 7.4 Hz, 2H), 2.45 (td, J = 7.4, 2.6 Hz, 2H), 2.10 (t, J = 2.5 Hz, 1H); 13C NMR (126 MHz, 
Chloroform-d) δ 155.33, 134.37, 125.18, 116.35, 82.67, 69.87, 34.82, 19.37; IR (neat cm-
1) 3404, 3271, 1587; HRMS (DART, M++H) m/z 179.0542 (calculated for C10H11OS 
179.0531) 
Synthesis of UCP1174 
S
N
N
NH2
H2N
OH
 
To alkyne (300 mg, 1.68 mmol), iodo-ethyl pyrimidine (220 mg, 0.84 mmol), CuI (7.98 
mg, 0.042 mmol), PdCl2(PPh3)2 (117.7 mg, 0.17 mmol), and potassium acetate (1,645 
mg, 16.76 mmol) was added followed by DMF (10 mL) and stirred at 65 ° C for an hour. 
The reaction mixture was quenched with solid NaHCO3 and filtered through cotton, and 
concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (1 % to 5% MeOH in CH2Cl2) to yield coupled pyrimidine as a white solid 
(42.1 mg, 16% yield); mp 138 0C; 1H NMR (500 MHz, Chloroform-d) δ 7.32 (d, J = 8.4 Hz, 
2H), 6.77 (d, J = 6.8 Hz, 2H), 2.96 (t, J = 6.7 Hz, 2H), 2.64 (m, J = 22.3, 7.1 Hz, 4H), 1.19 
(t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 172.62, 164.49, 160.22, 157.06, 
134.90, 123.19, 116.28, 97.24, 90.63, 74.64, 35.89, 29.35, 20.31, 12.58; IR (neat cm-1) 
3326, 1606, 1555, 1440; HRMS (DART, M++H) m/z 315.1245 (calculated for C16H19N4OS 
315.1123) 
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Synthesis of 3-((4-hydroxyphenyl)thio)butanal 
S
OH
O
 
To a solution of 4-mercapto phenol (500 mg, 3.96 mmol) in dry CH2Cl2 (20 mL), TEA 
(0.610 mL, 4.35 mmol) was added and stirred. Crotonaldehyde (0.490 mL, 5.95 mmol) in 
dry CH2Cl2 (15 mL) was added dropwise over an hour and allowed to stir for 16 hours. 
Quenched with NH4Cl and extracted with CH2Cl2 (150 mL) and concentrated. Purified by 
gradient flash chromatography (5% to 20% EtOAc in Hexanes) to yield pure product as 
colorless translucent liquid (420 mg, 54% yield); 1H NMR (500 MHz, Chloroform-d) δ 9.71 
(s, 1H), 7.34 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 3.52 (h, J = 6.8 Hz, 1H), 2.76 – 
2.47 (m, 2H), 1.31 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 201.64, 
156.30, 136.69, 123.27, 116.21, 50.07, 38.72, 21.14; IR (neat cm-1) 3347, 2962, 2924, 
1709, 1598, 1581, 1493; HRMS (DART, M++H) m/z 197.0661 (calculated for C10H13O2S 
197.0636) 
Synthesis of UCP1176 
S
N
N
NH2
H2N
OH
 
Step 1 A solution of the aldehyde (300 mg, 1.53 mmol) in MeOH (2 mL) was cooled to 0 
°C and a solution of Ohira-Bestmann reagent (0.534 mL, 2.29 mmol) in MeOH (14 mL) 
was added. To the reaction mixture K2CO3 (422 mg, 3.06 mmol) was added and stirred 
for 4 hours. The reaction was then quenched with NH4Cl and extracted with EtOAc (100 
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mL) and concentrated. The crude product was purified by flash chromatography (5% 
EtOAc) to give the desired alkyne with inseparable impurity. 
Step 2 To alkyne (60.8 mg, 0.32 mmol), iodo-ethyl pyrimidine (41.8 mg, 0.16 mmol), CuI 
(1.52 mg, 0.0080 mmol), PdCl2(PPh3)2 (22.2 mg, 0.03 mmol), and potassium acetate 
(155.3 mg, 1.58 mmol) was added followed by DMF (5 mL) and stirred at 65 ° C for an 
hour. The reaction mixture was quenched with solid NaHCO3 and filtered through cotton, 
and concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (1 % to 5% MeOH in CH2Cl2) to yield coupled pyrimidine as a white solid 
(13.8 mg, 27% yield); mp 170 0C; 1H NMR (500 MHz, Chloroform-d) δ 7.30 (d, J = 8.6 Hz, 
2H), 6.72 (d, J = 8.7 Hz, 2H), 3.15 (h, J = 6.4 Hz, 1H), 2.60 (q, J = 7.6 Hz, 2H), 2.55 (d, J 
= 6.0 Hz, 2H), 1.29 (d, J = 6.8 Hz, 3H), 1.16 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, 
Chloroform-d) δ 172.60, 164.56, 160.23, 157.39, 136.64, 122.04, 116.02, 96.31, 90.66, 
44.02, 29.41, 27.34, 20.25, 12.56; IR (neat cm-1) 3326, 1606, 1555, 1440; HRMS (DART, 
M++H) m/z 329.1440 (calculated for C17H21N4OS 329.1436) 
Synthesis of 3-((4-hydroxyphenyl)thio)-3-methylbutanal 
S
OH
O
 
To a solution of 4-mercapto phenol (500 mg, 3.96 mmol) in dry CH2Cl2 (20 mL), TEA 
(0.610 mL, 4.35 mmol) was added and stirred. 3-methyl-2-butenal (0.49 mL, 5.15 mmol) 
in dry CH2Cl2 (15 mL) was added dropwise over an hour and allowed to stir for 16 hours. 
Quenched with NH4Cl and extracted with CH2Cl2 (150 mL) and concentrated. Purified by 
gradient flash chromatography (5% to 20% EtOAc in Hexanes) to yield pure product as 
colorless translucent liquid (510 mg, 60% yield); 1H NMR (500 MHz, Chloroform-d) δ 9.90 
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(s, 1H), 7.35 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 6.73 (s, 1H), 2.48 (d, J = 2.6 
Hz, 2H), 1.38 (s, 6H); 13C NMR (126 MHz, Chloroform-d) δ 203.86, 157.30, 139.22, 
121.39, 116.10, 53.98, 45.88, 28.93; IR (neat cm-1) 3373, 2963, 2928, 2865, 1709, 1599, 
1581; HRMS (DART, M++H) m/z 211.0803 (calculated for C11H15O2S 211.0793) 
Synthesis of UCP1192 
S
N
N
NH2
H2N
OH
 
Step 1 A solution of the aldehyde (490 mg, 2.24 mmol) in MeOH (2 mL) was cooled to 0 
°C and a solution of Ohira-Bestmann reagent (0.62 mL, 2.68 mmol) in MeOH (14 mL) 
was added. To the reaction mixture K2CO3 (620 mg, 2.70 mmol) was added and stirred 
for 4 hours. The reaction was then quenched with NH4Cl and extracted with EtOAc (100 
mL) and concentrated. The crude product was purified by flash chromatography (5% 
EtOAc) to give the desired alkyne with inseparable impurity. 
Step 2 To alkyne (142 mg, 0.690 mmol), iodo-ethyl pyrimidine (72.6 mg, 0.280 mmol), 
CuI (2.66 mg, 0.0140 mmol), PdCl2(PPh3)2 (19.3 mg, 0.0300 mmol), and potassium 
acetate (275 mg, 2.80 mmol) was added followed by DMF (5 mL) and stirred at 65 ° C for 
an hour. The reaction mixture was quenched with solid NaHCO3 and filtered through 
cotton, and concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient 
flash chromatagrophy (1 % to 5% MeOH in CH2Cl2) to yield coupled pyrimidine as a white 
solid (25.9 mg, 28% yield); mp 168 0C; 1H NMR (500 MHz, Methanol-d4) δ 7.40 (d, J = 
8.5 Hz, 2H), 6.79 (d, J = 8.5 Hz, 2H), 2.68 (q, J = 7.6 Hz, 2H), 2.55 (s, 2H), 1.34 (s, 6H), 
1.23 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 171.96, 164.96, 160.49, 
158.41, 138.77, 120.50, 115.60, 96.28, 90.36, 75.37, 33.31, 29.14, 27.70, 13.54, 12.36; 
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IR (neat cm-1) 3320, 2964, 1556, 1479; HRMS (DART, M++H) m/z 343.1562 (calculated 
for C18H23N4OS 343.1593) 
Synthesis of 3-((4-hydroxyphenyl)thio)pentanal 
S
OH
O
 
To a solution of 4-mercapto phenol (500 mg, 3.96 mmol) in dry CH2Cl2 (20 mL), TEA 
(0.610 mL, 4.35 mmol) was added and stirred. Trans-2-pentenal (0.540 mL, 5.55 mmol) 
in dry CH2Cl2 (15 mL) was added dropwise over an hour and allowed to stir for 16 hours. 
Quenched with NH4Cl, extracted with CH2Cl2 (150 mL), and concentrated. Purified by 
gradient flash chromatography (5% to 20% EtOAc in Hexanes) to yield pure product as 
colorless translucent liquid (422 mg, 51% yield); 1H NMR (500 MHz, Chloroform-d) δ 9.74 
(s, 1H), 7.34 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 3.32 (p, J = 6.7 Hz, 1H), 2.63 
(dd, J = 6.4, 1.9 Hz, 2H), 1.63 (pd, J = 7.2, 2.7 Hz, 2H), 1.07 (t, J = 7.3 Hz, 3H); 13C NMR 
(126 MHz, Chloroform-d) δ 201.81, 156.22, 136.73, 123.20, 116.19, 48.04, 45.83, 27.58, 
11.46; IR (neat cm-1) 3335, 2967, 2930, 2875, 1713, 1598, 1580; HRMS (DART, M++H) 
m/z 211.0807 (calculated for C11H15O2S 211.0793) 
Synthesis of UCP1193  
S
N
N
NH2
H2N
OH
 
Step 1 A solution of the aldehyde (400 mg, 1.90 mmol) in MeOH (2 mL) was cooled to 0 
°C and a solution of Ohira-Bestmann reagent (0.530 mL, 2.28 mmol) in MeOH (14 mL) 
was added. To the reaction mixture K2CO3 (527 mg, 3.81 mmol) was added and stirred 
for 4 hours. The reaction was then quenched with NH4Cl and extracted with EtOAc (100 
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mL) and concentrated. The crude product was purified by flash chromatography (5% 
EtOAc) to give the desired alkyne with inseparable impurity. 
Step 2 To alkyne (130 mg, 0.630 mmol), iodo-ethyl pyrimidine (111 mg, 0.420 mmol), 
Josiphos Cu (1.7 mg, 1.05x10-3 mmol), Pd(PPh3)4 (48.6 mg, 0.0400 mmol), and 
potassium acetate (206 mg, 2.10 mmol) was added followed by DMF (5 mL) and stirred 
at 85 ° C for an hour. The reaction mixture was quenched with solid NaHCO3 and filtered 
through cotton, and concentrated by azeotroping with toluene (3 x 50 mL) and purified by 
gradient flash chromatography (1 % to 5% MeOH in CH2Cl2) to yield coupled pyrimidine 
as a white solid (38.1 mg, 27% yield); mp 81 0C; 1H NMR (400 MHz, Methanol-d4) δ 7.36 
(d, J = 8.5 Hz, 2H), 6.77 (d, J = 8.6 Hz, 2H), 2.99 (p, J = 6.1 Hz, 1H), 2.72 – 2.58 (m, 4H), 
1.67 (ddp, J = 28.6, 14.4, 7.0 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H), 1.07 (t, J = 7.3 Hz, 3H); 
13C NMR (101 MHz, Methanol-d4) δ 172.07, 164.86, 160.52, 157.61, 136.42, 121.80, 
115.85, 96.17, 90.32, 74.88, 51.08, 29.12, 26.41, 24.75, 12.29, 11.10; IR (neat cm-1) 
3326, 2963, 2923, 1559, 1480; HRMS (DART, M++H) m/z 343.1613 (calculated for 
C18H23N4OS 343.1593) 
Synthesis of 3-(pyridin-4-yl)propan-1-ol 
HO
N  
To a solution of (Formylmethyl)triphenylphosphonium chloride (2,340 mg, 6.86 mmol) in 
THF (15 mL) 1.0 M potassium tert-butoxide in THF (6.86 mL, 6.86 mmol) was added and 
allowed to stir for 15 minutes. 4-Pyridinecarboxaldehyde (0.620 mL, 6.54 mmol) was then 
added and allowed to stir for 1 hour.  The reaction mixture was quenched with NH4Cl, 
extracted with EtOAc (150 mL), and concentrated. The crude product was dissolved in 
EtOH (50 mL), and Pd/C (1 g) was added. The reaction flask was sealed and purged with 
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hydrogen gas and left stirring under hydrogen overnight. The reaction was filtered through 
celite and purified by flash chromatography (30% to 70% EtOAc in Hexanes) to yield a 
brown liquid (337 mg, 38% yield); Matched previous reported data. 
Synthesis of 3-(pyridin-4-yl)propan-1-al 
O
N  
To a solution of 3-(pyridin-4-yl)propan-1-ol (300 mg, 2.22 mmol) in DCM (15 mL), DMP 
(1.41 g, 3.33 mmol) was added and allowed to stir for 2 hours. Then 0.05 mL of dH2O 
was added dropwise. The reaction was then quenched with Na2S2O3 and NaHCO3, 
extracted with EtOAc (150 mL), and concentrated. It was then purified by flash 
chromatography (20% to 60% EtOAc in Hexanes) to yield a red-brown liquid (215 mg, 
72.9% yield); Matched previous reported data 
Synthesis of 5-(pyridin-4-yl)pent-1-yn-3-ol 
 
 
To a solution of Trimethylsilylacetylene (0.680 mL, 4.84 mmol) in THF (16 mL) at -78 0C, 
2.5 M n-BuLI in Hexanes (1.94 mL, 4.84 mmol) was added dropwise. The reaction was 
allowed to stir for 30 minutes before 3-(pyridin-4-yl)propan-1-al (215 mg, 1.61 mmol) in 
THF (2 mL) was added dropwise. The reaction mixture was allowed to warm to room 
temperature and after 2 hours was quenched with NH4Cl, extracted with EtOAc, and 
concentrated. The product was then dissolved in dry MeOH and K2CO3 (667 mg, 4.83 
mmol) was added and stirred at room temp. for 4 hours. The reaction was quenched with 
NaHCO3, extracted with EtOAc, and concentrated. It was then purified by flash 
chromatagrophy (50% to 80% EtoAC in Hexanes) to yield a brown solid (135 mg, 52% 
N
OH
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yield in 2 steps); mp 58 0C; 1H NMR (500 MHz, Chloroform-d) δ 8.42 (d, J = 6.1 Hz, 2H), 
7.14 (d, J = 6.1 Hz, 2H), 6.09 (s, 1H), 4.38 (td, J = 6.5, 2.1 Hz, 1H), 2.81 (t, J = 8.0 Hz, 
2H), 2.46 (d, J = 2.1 Hz, 1H), 2.03 (tq, J = 13.5, 6.6, 5.9 Hz, 2H); 13C NMR (126 MHz, 
Chloroform-d) δ 151.41, 148.99, 124.19, 85.23, 72.77, 60.40, 37.94, 30.70; IR (neat cm-
1) 3201, 3134, 2926, 2834, 1601; HRMS (DART, M++H) m/z 162.0930 (calculated for 
C10H12NO 162.0919). 
Synthesis of UCP1194 
 
 
 
To alkyne (100 mg, 0.620 mmol), iodo-ethyl pyrimidine (126 mg, 0.480 mmol), JosiPhos 
Copper (2.00 mg, 0.00120 mmol), Pd(PPh3)4 (55.2 mg, 0.0480 mmol), and TEA (0.130 
mL, 0.950 mmol) was added followed by DMF (5 mL) and stirred at 85 ° C for an hour. 
The reaction mixture was quenched with solid NaHCO3 and filtered through cotton, and 
concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (EtOAc followed by 1 % to 5% MeOH in CH2Cl2) to yield coupled 
pyrimidine as a white solid (33.9 mg, 24% yield); mp 135 0C; 1H NMR (500 MHz, 
Methanol-d4) δ 8.39 (d, J = 4.6 Hz, 2H), 7.18 (d, J = 4.5 Hz, 2H), 4.58 (t, J = 6.5 Hz, 1H), 
2.82 (t, J = 7.9 Hz, 2H), 2.62 (q, J = 7.6 Hz, 2H), 2.06 (qq, J = 14.0, 7.9 Hz, 2H), 1.19 (t, 
J = 7.6 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 171.29, 164.56, 160.10, 152.00, 
148.69, 124.37, 98.82, 89.36, 76.91, 63.08, 61.33, 38.15, 30.81, 28.72, 12.17. IR (neat 
cm-1) 3325, 3183, 2971, 2933, 2872, 1606, 1570, 1548; HRMS (DART, M++H) m/z 
298.1667 (calculated for C16H20N5O 298.1668) 
N
N
N
NH2
H2N
OH
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Synthesis of homopropargyl analine sulfide  
 
 
To a solution of 4-mercapto aniline (900 mg, 7.19 mmol) in Acetonitrile (20 mL), K2CO3 
(1,990 mg, 14.4 mmol) was added and allowed to stir for 10 minutes. 4-Bromo-butyne 
(1.35 mL, 14.4 mmol) was added. The reaction vessel was sealed and the mixture was 
stirred at 90 °C for an hour. The reaction mixture was then diluted with water (25 mL) and 
extracted with EtOAc (150 mL) and then dried with Na2SO4 and concentrated. The crude 
product was purified by flash chromatography (10% to 40 % EtOAc in Hexanes) to yield 
pure product as a brown solid (840 mg, 72% yield); mp 58 0C; 1H NMR (400 MHz, 
Chloroform-d) δ 7.29 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 8.5 Hz, 2H), 3.75 (s, 2H), 2.91 (dd, 
J = 7.9, 7.1 Hz, 2H), 2.42 (td, J = 7.4, 2.6 Hz, 2H), 2.03 (t, J = 2.6 Hz, 1H); 13C NMR (126 
MHz, Chloroform-d) δ 146.58, 134.81, 121.73, 115.62, 82.87, 69.54, 35.33, 19.43; ; IR 
(neat cm-1) 3424, 3334, 3273, 1620, 1592, 1491; HRMS (DART, M++H) m/z 178.0702 
(calculated for C10H12NS 178.0690) 
Synthesis of UCP1199 
 
 
 
To alkyne (111 mg, 0.630 mmol), iodo-ethyl pyrimidine (100 mg, 0.370 mmol), JosiPhos 
Copper (1.50 mg, 0.000920 mmol), Pd(PPh3)4 (42.5 mg, 0.0370 mmol), and KOAc (181 
mg, 1.84 mmol) was added followed by DMF (5 mL) and stirred at 85 ° C for an hour. The 
reaction mixture was quenched with solid NaHCO3 and filtered through cotton, and 
S
NH2
S
N
N
NH2
H2N
NH2
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concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (EtOAc followed by 1 % to 5% MeOH in CH2Cl2) to yield coupled 
pyrimidine as a tan solid (35.9 mg, 31% yield); mp 139 0C; 1H NMR (500 MHz, Methanol-
d4) δ 7.26 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.1 Hz, 2H), 2.94 (t, J = 6.8 Hz, 2H), 2.70 – 
2.57 (m, 4H), 1.20 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 172.18, 164.64, 
160.34, 147.17, 134.82, 120.93, 115.75, 97.25, 90.43, 74.31, 35.97, 29.17, 20.10, 12.39; 
IR (neat cm-1) 3325, 3183, 2971, 2933, 2872, 1606, 1570, 1548; HRMS (DART, M++H) 
m/z 314.1421 (calculated for C16H20N5S 314.1439) 
Synthesis of ethyl 2-(4-(but-3-yn-1-ylthio)phenyl)acetate 
 
 
 
To a solution of 4-mercapto-phenylacetic acid (320 mg, 1.90 mmol) in EtOH (10 mL), 
sulfuric acid (0.100 mL, 1.90 mmol) was added and allowed to stir for 2 hours. The 
reaction was then quenched with NaHCO3 and extracted with EtOAc (3 x 25 mL). The 
extracts were combined, washed with brine (40 mL), dried (Na2SO4), and concentrated. 
The crude mixture was then dissolved in MeCN (10 mL) and K2CO3 was added and 
allowed to stir for 10 minutes. Then, 4-bromobutyne (0.360 mL, 3.80 mmol) was added 
and heated to 85 0C and stirred for 2 hours before being diluted with H2O and extracted 
with EtOAc (3 x 25 mL). The extracts were combined, washed with brine (45 mL), dried 
(Na2SO4), and concentrated. The crude product was then purified by flash 
chromatography (0% to 20% EtOAc in hexanes) to yield a clear liquid (296 mg, 63% yield 
2 steps); 1H NMR (500 MHz, Chloroform-d) δ 7.36 (d, J = 8.2 Hz, 2H), 7.25 (d, J = 8.3 Hz, 
OEt
O
S
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2H), 4.18 (q, J = 7.2 Hz, 2H), 3.61 (s, 2H), 3.08 (t, J = 7.4 Hz, 2H), 2.50 (td, J = 7.5, 2.5 
Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 171.30, 133.91, 
132.72, 130.35, 129.99, 82.27, 69.79, 60.94, 40.89, 32.99, 19.40, 14.22; IR (neat cm-1) 
3292, 2981, 2934, 1730, 1494; HRMS (DART, M++H) m/z 249.0957 (calculated for 
C14H17O2S 249.0957) 
Synthesis of UCP1201 
OEt
O
S
N
N
NH2
H2N  
To alkyne (196 mg, 0.790 mmol), iodo-ethyl pyrimidine (160 mg, 0.610 mmol), JosiPhos 
Copper (2.5 mg, 0.00150 mmol), Pd(PPh3)4 (70.3 mg, 0.0610 mmol), and KOAc (298 
mg, 3.0 mmol) was added followed by DMF (7 mL) and stirred at 85 ° C for an hour. The 
reaction mixture was quenched with solid NaHCO3 and filtered through cotton, and 
concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (EtOAc followed by 1 % to 5% MeOH in CH2Cl2) to yield coupled 
pyrimidine as a clear semi-solid (50.2 mg, 22% yield); 1H NMR (500 MHz, Chloroform-d) 
δ 7.40 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 5.52 (s, 2H), 5.18 (s, 2H), 4.19 (q, J = 
7.1 Hz, 2H), 3.62 (s, 2H), 3.16 (t, J = 6.9 Hz, 2H), 2.79 (t, J = 6.9 Hz, 2H), 2.69 (q, J = 7.6 
Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, Chloroform-
d) δ 173.21, 171.39, 164.70, 160.86, 133.64, 132.95, 130.77, 130.06, 96.50, 90.28, 75.44, 
61.02, 40.88, 34.00, 29.57, 20.51, 14.20, 12.63; ; IR (neat cm-1) 3325, 3208, 2976, 2931, 
2873, 1731, 1615, 1560, 1515, 1495; HRMS (DART, M++H) m/z 385.1683 (calculated for 
C20H25N4O2S 385.1698) 
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Synthesis of UCP1202 
CO2H
S
N
N
NH2
H2N  
UCP1201 (40 mg, 0.104 mmol) was dissolved in THF (0.5 mL) then LiOH (17.4 mg, 0.730 
mmol) in H2O (0.4 mL) was added and allowed to react at room temperature for 4 hours. 
The reaction was quenched with 0.1M HCl in H2O and extracted with DCM to yield white 
solid which was then washed with EtOAc and filtered through funnel with fritted disk to 
yield the carboxylic acid (39.2 mg, 98% yield); mp 178 0C; 1H NMR (500 MHz, Methanol-
d4) δ 7.40 (d, J = 7.9 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 3.60 (s, 2H), 3.21 (t, J = 6.8 Hz, 
2H), 2.82 (t, J = 6.8 Hz, 2H), 2.78 (q, J = 7.6 Hz, 2H), 1.31 (t, J = 7.6 Hz, 3H); 13C NMR 
(126 MHz, Methanol-d4) δ 173.89, 165.22, 160.14, 154.40, 133.55, 133.52, 130.09, 
129.83, 99.07, 92.23, 70.41, 40.01, 32.62, 25.09, 19.75, 10.98; IR (neat cm-1) 3331, 3174, 
2910, 1696, 1664, 1645, 1526, 1496; HRMS (ESI, M++H) m/z 357.1358 (calculated for 
C18H20N4O2S 357.1395) 
Synthesis of homopropargyl 3,4 dimethoxy sulfide  
S
OMe
OMe
 
To a solution of 3,4-dimethoxythiophenol (500 mg, 2.94 mmol) in Acetonitrile (30 mL), 
K2CO3 (609 mg, 4.41 mmol) was added and allowed to stir for 10 minutes. 4-Bromo-
butyne (0.41 mL, 4.41 mmol) was added. The reaction vessel was sealed and the mixture 
was stirred at 90 °C for an hour. The reaction mixture was then diluted with water (25 
mL), extracted with EtOAc (150 mL), and then dried with Na2SO4 and concentrated. The 
crude product was purified by flash chromatography (10% to 40 % EtOAc in Hexanes) to 
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yield pure product as a colorless liquid (642 mg, 98% yield); 1H NMR (500 MHz, 
Chloroform-d) δ 6.95 (dd, J = 8.2, 2.1 Hz, 1H), 6.92 (d, J = 2.1 Hz, 1H), 6.74 (d, J = 8.2 
Hz, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 2.91 (t, J = 7.4 Hz, 2H), 2.37 (td, J = 7.5, 2.6 Hz, 2H), 
2.00 (t, J = 2.6 Hz, 1H); 13C NMR (126 MHz, Chloroform-d) δ 149.12, 148.85, 125.51, 
125.02, 115.65, 111.67, 82.41, 69.60, 55.88, 55.85, 34.63, 19.37; IR (neat cm-1) 3287, 
3000, 2932, 2835, 1582, 1501; HRMS (DART, M++H) m/z 223.0791 (calculated for 
C12H15O2S 223.0793) 
Synthesis of UCP1204 
S
OMe
N
N
NH2
H2N
OMe
 
To alkyne (108 mg, 0.490 mmol), iodo-ethyl pyrimidine (100 mg, 0.380 mmol), JosiPhos 
Copper (1.50 mg, 0.000920 mmol), Pd(PPh3)4 (42.5 mg, 0.0380 mmol), and KOAc (180 
mg, 1.84 mmol) was added followed by DMF (4 mL) and stirred at 85 ° C for overnight. 
The reaction mixture was quenched with solid NaHCO3 and filtered through cotton, and 
concentrated by azeotroping with toluene (3 x 50 mL) and purified by gradient flash 
chromatagrophy (50-90% EtOAc in Hexanes) to yield coupled pyrimidine  as an orange 
solid (40.7 mg, 30% yield); mp 129 0C; 1H NMR (500 MHz, Chloroform-d) δ 7.10 (dd, J = 
8.3, 2.1 Hz, 1H), 7.05 (d, J = 2.1 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 5.56 (s, 2H), 5.12 (s, 
2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.07 (t, J = 6.9 Hz, 2H), 2.74 (t, J = 6.9 Hz, 2H), 2.69 (q, J 
= 7.6 Hz, 2H), 1.25 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 173.15, 
164.76, 160.84, 149.19, 149.12, 125.66, 125.09, 116.04, 111.67, 96.73, 90.38, 75.40, 
56.02, 55.98, 35.75, 29.58, 20.45, 12.64; IR (neat cm-1) 3440, 3313, 3095, 2932, 1640, 
1555, 1495; HRMS (DART, M+H) m/z 359.1517 (calculated for C18H23N4O2S 359.1542) 
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Synthesis of UCP1203 
 
 
 
To a solution of UCP1204 (33.5 mg, 0.102 mmol) in DCM (1 mL), BBr3 (0.0870 mL, 0.914 
mmol) was added and allowed to stir for 2 hours. After the reaction was complete the 
reaction was quenched with concentrated NaHCO3 in water and extracted with DCM to 
give pure white solid (7.47 mg, 22% yield); mp 168 0C; 1H NMR (500 MHz, DMSO-d6) δ 
9.10 (s, 1H), 9.10 (s, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.77 – 6.74 (m, 1H), 6.73 (d, J = 8.1 
Hz, 1H), 6.33 (s, 2H), 6.14 (s, 2H), 3.01 (t, J = 7.0 Hz, 2H), 2.65 (t, J = 7.0 Hz, 2H), 2.55 
(q, J = 7.6 Hz, 2H), 1.13 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 164.95, 
161.53, 146.19, 145.70, 123.66, 123.29, 119.64, 116.69, 96.72, 88.43, 75.87, 34.91, 
29.48, 29.18, 20.52, 12.94; IR (neat cm-1) 3472, 3352,3191, 2915, 1607, 1581, 
1555,1507; HRMS (ESI, M++H) m/z 331.1208 (calculated from C16H19N4O2S 331.1229) 
S
OH
N
N
NH2
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